Administration of the MHRA approved vaccine differs between adults and children depending on their age at the time of vaccination
The Medicines and Healthcare products Regulatory Agency (MHRA) has today approved an adapted Pfizer/BioNTech COVID-19 vaccine, branded as Comirnaty JN.1, targeting the JN.1 COVID-19 subvariant.
This new vaccine is now authorised for use in both adults and children from infancy.
The Comirnaty JN.1 vaccine has been rigorously evaluated and approved under the International Recognition Procedure.
It has met the UK regulator’s stringent standards for safety, quality, and effectiveness.
This vaccine is designed to stimulate the production of antibodies and blood cells to enhance the immune system’s ability to combat COVID-19.
Four different formulations of the Comirnaty JN.1 vaccine have been cleared by the MHRA.
As with all vaccines, the MHRA will continue to monitor the safety of Comirnaty JN.1 closely.
The patient information leaflet (PIL) accompanying the vaccine provides a comprehensive list of potential side effects.
Patients are encouraged to consult their doctor, pharmacist, or nurse if they experience any side effects, including those not specified in the PIL or product information.
Additionally, the regulatory organisation has provided patients and caregivers platform to report any suspected side effects through the Yellow Card scheme.
MHRA has highlighted that reporting side effects is crucial for ongoing safety assessments and helps ensure the continued effectiveness and safety of the vaccine.
